Single agent activity of rhizoxin in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group
| Autor: | Kaplan, S., Hanauske, A. R., Pavlidis, Nicholas, Bruntsch, U., Velde, A. Te, Wanders, J., Heinrich, B., Verweij, J. |
|---|---|
| Přispěvatelé: | Pavlidis, Nicholas [0000-0002-2195-9961] |
| Jazyk: | angličtina |
| Rok vydání: | 1996 |
| Předmět: |
Adult
Diarrhea Male Neutropenia Fever Vomiting Clinical article Article Lactones Lung neoplasms Antibiotics Humans Phase 2 clinical trial Middle aged Aged Priority journal Antineoplastic activity Stomatitis Carcinoma Non-small-cell lung Headache Outpatient Alopecia Anemia Nausea Leukopenia Blood toxicity Skin toxicity Thrombocytopenia Antineoplastic Cancer survival Multicenter study Phase ii Hematopoiesis Rhizoxin Clinical trial Antineoplastic agent Lung non small cell cancer Female Intravenous drug administration Cancer chemotherapy Macrolides Phlebitis Non-small-cell lung cancer Malaise Human Drug hypersensitivity |
| Zdroj: | British journal of cancer |
| Popis: | In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was given as an i.v. bolus injection at 2 mg m-2 once every 3 weeks in an outpatient setting. Prophylactic antiemetics were not routinely given. Of the 29 eligible patients, nine had been treated surgically and three had received radiotherapy. The main toxic effects observed were stomatitis (34% of cycles) and neutropenia (41% of cycles). Neutropenic fever was rare (3% of cycles). Twenty-seven patients were evaluable for response. There were four partial responses (15%), while 13 patients (48%) showed stabilisation of their disease. The median duration of response was 7 months (range 6.0-10.7 months) and median survival from the start of rhizoxin treatment was 6 months (range 2-14.7 months). Rhizoxin as single agent shows activity in patients with advanced NSCLC. 73 3 403 405 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|